Skip to content

US · TNXP · BIOTECHNOLOGY

Tonix Pharmaceuticals Holding Corp. (TNXP) intrinsic value and stock valuation

$2.38as of 2026-11-21 · Mkt cap 191.77M

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Tonix Pharmaceuticals Holding Corp. DCF and intrinsic value

InvestorsCraft values TNXP with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from TNXP’s statements →

Tonix Pharmaceuticals Holding Corp. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Berkeley Heights, NJ 07928 tonixpharma.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$13.1M
20112025
Net income
-$-124.02M
20112025
Free cash flow
-$-103.21M
20112025
Total equity
$245.2M+22.8% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$13.1M$10.1M$7.77M$0.00$0.00
Operating income-$-125.7M-$-136.7M-$-118.38M-$-112.09M-$-92.31M
Net income-$-124.02M-$-130.04M-$-116.66M-$-110.22M-$-92.29M
EPSd-$-14.57M-$-57.54M-$-63.75M-$-35.9M—
Operating cash flow-$-99.84M-$-60.92M-$-102M-$-98.05M-$-75.56M
Capital expenditure-$-3.37M-$-120K-$-7.89M-$-48.15M-$-35.31M
Free cash flow-$-103.21M-$-61.05M-$-109.9M-$-146.2M-$-110.86M
Total assets$277.2M$162.9M$154.5M$225.7M$240.9M
Total debt$1.31M$5.3M$9.81M$760K$960K
Net debt-$-206.33M-$-93.48M-$-15.13M-$-119.47M-$-177.7M
Total equity$245.2M$139.6M$105.5M$207.2M$218.7M
Cash and short-term investments$207.6M$98.8M$25M$120.2M$178.7M
Income statement
20252024202320222021
Revenue$13.1M$10.1M$7.77M$0.00$0.00
Cost of revenue$8.56M$7.76M$4.74M$0.00$0.00
Gross profit$4.54M$2.33M$3.03M$0.00$0.00
Research and development expenses$44.5M$40.5M$86.7M$81.9M$68.8M
Selling, general and administrative expenses$85.8M$40.1M$34.8M$30.2M$23.5M
Other expenses$0.00$58.5M$0.00$0.00$0.00
Operating expenses$130.3M$139M$121.4M$112.1M$92.3M
Cost and expenses$138.8M$146.8M$126.2M$112.1M$92.3M
Interest income$4.15M$0.00$0.00$1.87M$30K
Interest expense$90K$0.00$0.00$0.00$0.00
Depreciation and amortization$1.93M$3.42M$4.29M$1.25M$50K
Ebitda-$-122.01M-$-74.32M-$-112.37M-$-108.97M-$-92.24M
Operating income-$-125.7M-$-136.7M-$-118.38M-$-112.09M-$-92.31M
Total other income/expenses, net$1.68M$6.67M$1.72M$1.87M$30K
Income before tax-$-124.02M-$-130.04M-$-116.66M-$-110.22M-$-92.29M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-124.02M-$-130.04M-$-116.66M-$-110.22M-$-92.29M
Weighted average shares outstanding$8.51M$2.26M$1.83M$3.07M$0.00
Weighted average diluted shares outstanding$8.51M$2.26M$1.83M$3.07M$0.00
Balance sheet
20252024202320222021
Cash and short-term investments$207.6M$98.8M$25M$120.2M$178.7M
Net receivables$9.76M$7.9M$4.59M$8.04M$7.73M
Inventory$6.01M$8.41M$14.2M$0.00$0.00
Total current assets$228.9M$119M$47.8M$130.8M$189.1M
Property, plant and equipment, net$46M$42.8M$94.9M$94.5M$51.5M
Goodwill and intangible assets$120K$120K$10.7M$120K$120K
Long-term investments$2.17M$900K$0.00$0.00$240K
Total non-current assets$48.3M$43.9M$106.7M$94.9M$51.9M
Total assets$277.2M$162.9M$154.5M$225.7M$240.9M
Accounts payable$8.11M$4.55M$3.78M$8.07M$13.3M
Short-term debt$120K$270K$2.62M$430K$490K
Deferred revenue$3.42M$1.82M$2.98M$3.27M$2.83M
Total current liabilities$30.8M$18.3M$18.9M$18.2M$21.7M
Long-term debt$1.18M$5.03M$7.19M$330K$470K
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$1.18M$5.03M$30.1M$330K$470K
Capital lease obligations$1.31M$630K$900K$760K$960K
Total liabilities$32M$23.3M$48.9M$18.5M$22.2M
Common stock$10K$0.00$60K$10K$500K
Retained earnings-$-854.72M-$-730.69M-$-600.66M-$-470.04M-$-359.82M
Accumulated other comprehensive income (loss)-$-290K-$-260K-$-230K-$-170K-$-90K
Total equity$245.2M$139.6M$105.5M$207.2M$218.7M
Total investments$2.17M$900K$0.00$0.00$240K
Total debt$1.31M$5.3M$9.81M$760K$960K
Net debt-$-206.33M-$-93.48M-$-15.13M-$-119.47M-$-177.7M
Cash flow statement
20252024202320222021
Net income-$-124.02M-$-130.04M-$-116.66M-$-110.22M-$-92.29M
Depreciation and amortization$1.93M$3.42M$4.29M$1.25M$50K
Stock-based compensation$6.02M$4.78M$9.28M$10.9M$7.9M
Change in working capital$8.54M$5.78M-$-40K-$0.00$5.78M
Accounts receivable-$-2.62M-$-3.68M$0.00$0.00$0.00
Inventory$1.73M$3.74M$60K$0.00$0.00
Accounts payable$2.99M$930K-$-3.49M-$-1.04M$3.53M
Net cash provided by operating activities-$-99.84M-$-60.92M-$-102M-$-98.05M-$-75.56M
Investments in property, plant and equipment-$-3.37M-$-120K-$-7.89M-$-48.15M-$-35.31M
Acquisitions, net$0.00$0.00-$-22.17M$0.00$0.00
Net cash used for investing activities-$-4.53M-$-120K-$-29.07M-$-48.15M-$-35.31M
Common stock issued$237.9M$140.2M$18.9M$94.5M$212.4M
Common stock repurchased-$-13.76M$0.00-$-13.96M$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$214.5M$134.9M$36.5M$87.8M$212.5M
Net change in cash$110.1M$73.8M-$-94.62M-$-58.43M$101.6M
Cash at end of period$209.8M$99.7M$25.9M$120.5M$178.9M
Operating cash flow-$-99.84M-$-60.92M-$-102M-$-98.05M-$-75.56M
Capital expenditure-$-3.37M-$-120K-$-7.89M-$-48.15M-$-35.31M
Free cash flow-$-103.21M-$-61.05M-$-109.9M-$-146.2M-$-110.86M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Tonix Pharmaceuticals Holding Corp.

        Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical firm primarily operating in the clinical development stage. Its overarching mission involves the discovery, acquisition, advancement, and commercialization of novel therapeutic agents and diagnostic tools, all aimed at combating human illnesses and easing patient discomfort. The company boasts a comprehensive pipeline of potential treatments spanning several key medical fields: immunology, rare conditions, infectious diseases, and central nervous system (CNS) disorders. In the realm of immunology, Tonix is progressing with biologics designed to address organ transplant rejection, various autoimmune diseases, and certain forms of cancer. A prominent candidate here is TNX-1500, a humanized monoclonal antibody targeting CD40-ligand, which is being investigated for its utility in preventing both allograft and xenograft rejection, as well as in treating autoimmune disorders. Its rare disease initiatives include TNX-2900, a specific treatment candidate for Prader-Willi syndrome. The infectious disease segment features a diverse array of programs: TNX-801, a vaccine designed to offer protection against smallpox and monkeypox. TNX-1840 and TNX-1850, which are live virus vaccines based on the company's recombinant pox vaccine (RPV) platform, targeting COVID-19. TNX-3500, a small molecule antiviral drug for the treatment of acute COVID-19. TNX-102 SL, a small molecule medication under investigation for Long COVID, a persistent post-acute COVID-19 condition. Finally, the CNS portfolio encompasses both small molecules and biologics intended to manage pain, neurological conditions, psychiatric ailments, and addiction. Notably, TNX-102 SL is also in mid-Phase 3 development for alleviating fibromyalgia symptoms. Other CNS candidates include TNX-1900, which is being developed to prevent migraine headaches, and TNX-1300, a biologic aimed at treating cocaine intoxication. The company was established in 2007 and maintains its headquarters in Chatham, New Jersey.

        CEO
        Seth Lederman
        Employees
        142
        Beta
        1.65

        Explore

        Frequently asked questions

        What is the intrinsic value of Tonix Pharmaceuticals Holding Corp. (TNXP)?

        Tonix Pharmaceuticals Holding Corp. (TNXP) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is TNXP undervalued?

        TNXP trades at a price of $2.38 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.